云顶集团3118(中国)

    Therapeutic applications and effects of Lupinus angustifolius (Blue lupin) and its components. A systematic review with meta-analysis.

    Rafael Fernández Castillo

    Published: 2023-05-14 DOI: 10.17504/protocols.io.e6nvwjw6wlmk/v1
    AI 解读
    浏览 1350

    Abstract

    Reviews have focused on the blue lupin (Lupinus angustifolius) diet based on the reduction of analytical and anthropometric parameters in pathological populations or, alternatively, without population differentiation. The aim of this study was to investigate the scientific evidence on the biological properties of blue lupin (Lupinus angustifolius), its chemical constituents and their relevance for the treatment of health and disease in humans. The effect of the blue lupin diet was evaluated in conjunction with weight, BMI, blood glucose, LDL cholesterol and triglycerides. Boolean algorithms from various databases (PubMed, Scopus and Web of Science).

    Steps

    Therapeutic application and effects of Lupinus Angustifolius (Blue lupin) and its components. A systematic reviews with Mata-analysis

    1.

    Therapeutic applications and effects of Lupinus angustifolius (Blue lupin) and its components. A systematic review with meta-analysis.

    Citation

    Rafael Fernandez Castillo.Therapeutic applications and effects of Lupinus angustifolius (Blue lupin) and its components. A systematic review with meta-analysis.

    Review Question

    PICO (S) asks: "Population" participants with chronic pathologies" "Intervention": " blue lupin (Lupinus angustifolius) diet; "Control" "Group that did not lupinus diet". Results: "reduction of analytical and anthropometric parameters in pathological populations","Studies": "randomized controlled studies".

    Searches

    The scientific literature search was performed in electronic databases PubMed, Web of Sciences(WOS) ans SCOPUS.

    The search consisted of keywords related(“lupinus diet” OR “lupinus angustifolius dieting” OR “low carbohydrate diet” OR“low carbohydrate lupinus diet” OR “very low carbohydrate lupinus diet”) AND (“body composition” OR “fat-free mass” OR “lean body mass” OR “LBM” OR “FFM”) AND (“resistance insulin” OR “muscle” OR “muscle mass” OR“diabetes” OR “blood lipids” OR “antioxidants” OR “cancer” OR “anti-inflammatory”).

    Types of study

    Systematic review & meta-analysis

    Condition or domain being studied

    Impact of the biological properties of blue lupine (Lupinus angustifolius), its chemical constituents and their relevance for the treatment of health and disease in humans.

    Participants/Populations

    Participants with chronic pathologies (men a women).

    Intervention (s)/exposure

    Aplicattion ofLupinus angustifolius (Blue lupin)diets based on the reduction of analytical and anthropometric parameters.

    Comparator (s)/Control

    Control group take and consumes lupinus diet.

    Context

    Advanced participants with application of lupinus diet.

    Main (Outcome)

    Maintenance or decreased of analytical and anthropometric parameters.

    Meassure of effect ct

    Not applicable

    Additional outcomes

    None

    Measures of effect

    Not applicable

    Data extraction (selection and coding)

    The articles found were coded using the Endnote reference manager, and discrepancies regarding the interprepatinon of the extracted data were discussed by the researcher. In addition, the articles were filtered using the inclusion criteria:Studies published in Spanish and English and in the last 10 years were selected, in order to review the most current evidence; in this regard randomized trials, with a minimum duration of two weeks and analytical studies that evaluated the effects of lupines angustifolius therapy and its beneficial effects on chronic diseases were included. Studies that were not related to the subject or that did not provide relevant statical information, research conducted on animals, systematic reviews or meta-analyses or uncontrolled experimental studies and research without a control group were excluded

    The articles were selected according to their title and abstract. Articles that did not meet the inclusion criteria were discarted. In the second phase, the entire article was read and analyzed. Information was extracted from the articles on the numbre of participants, the type and duration or interventions, and characterictics of the population.

    Risk of bias (quality) assesment

    The risk of bias assesment will be carried out following the recommendations of the Cochrane Collaboration. For each study, seven domains were scored with high, low or unclear risk of bias. These domains were: sequence generation, al concealment, blinding of participants and staff, blinding of outcome assesment, incomplete outcome data, selective outcome reporting, and other issues considered.

    Strategy for data synthesis

    From each selected article, information was extracted including the name of the first author, the date of publication, the average age of the participants, and the gender of both the experimental and control groups, in addition to the study design, the participants, the duration, the composition of the diet, and the means and standard deviations (SD) of both groups. Data related to body weight, fasting glucose, BMI, LDL cholesterol, HDL, CT, TG were selected

    The results or this meta-analysis were presented with mean differences (MD) and 95% confidence intervan (CI). Heterogneity was also present, estimated by measuring its extent by the I2index. The authors examined the P value for this stastics and noted the presence of heterogeneity when P<0.05, compromising the validity of the pooled estimates. In addition, the I2index considered low heterogeneity (0-40%), moderate (30-60%), considerable (50-90%) o substantial (75-100%).

    Review team members and their organisational affiliations

    Rafael Fernandez Castillo(University of Granada, Granada, Spain).

    Type and method of review

    Meta-analysis, Systematic review

    Anticipated or actual start date

    14 January 2023

    Anticipated completion date

    30 May 2023

    Funding sources/sponsors

    No funding

    Conflicts of interest

    There are not conflicts of interest

    Language

    English

    Country

    Spain

    Stage of review

    Review ongoing

    推荐阅读

    Nature Protocols
    Protocols IO
    Current Protocols
    扫码咨询